Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Compiled: TRIAL PROCEDURE OTHER COUNTRIES and GENERAL

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 314
Posts 40,452
Boards Moderated 35
Alias Born 09/20/01
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
XenaLives Member Level  Thursday, 08/08/19 06:34:48 AM
Re: None
Post # of 230991 
Compiled: TRIAL PROCEDURE OTHER COUNTRIES and GENERAL COMMENTS: 08/08/19
________________________________________________________________________________________________________

The weaker the signal the higher the n or trial participants needs to be to show Stat Sig.
https://investorshub.advfn.com/boards/read_msg.aspx?mmessage_id=150305920

Novel trials designs such as “basket,” “umbrella,” etc
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150179911

Procedure and implications of post trial access to drugs:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149179546
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149180303

Sponsor has an obligation to monitor the trial as well as ensuring the Investigator is following protocol
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149408725

When to Stop a Clinical Trial Early for Benefit
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149768695

This could speed up and simplify and reduce cost of “precision enrollment” screening time:(from biostockclub)
https://neurosciencenews.com/artificial-intelligence-alzheimers-13097/

“The Future of Drug Trials Is Better Data and Continuous Monitoring” (from kevli33)
https://hbr.org/2019/05/the-future-of-drug-trials-is-better-data-and-continuous-monitoring

Multi-regional clinical trials and global drug development - 2016 changes in trial technique:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099281
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149099929
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149100322

As of January Anavex has a QPPV- needed for EU approval. (from TTTav66)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146643593
Qualified Person Responsible For Pharmacovigilance - Wikipedia
https://en.wikipedia.org/wiki/Qualified_Person_Responsible_For_Pharmacovigilance

Expedited approval in Asia
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145657979
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145658475

An example of provincial level drug approval in Canada: (from nidan7500)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148351451

Japan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148770129
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148770231
Japanese accelerated approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148389943

Reasons why it's good to be running trials in Australia...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140883830
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147033379


Patient Centricity And Social Media Are Changing Patient Recruitment (from Kevli33)
https://www.clinicalleader.com/doc/patient-centricity-and-social-media-are-changing-patient-recruitment-0001

PDD/AD trials in Australia/Spain-Australia and EU can exchange scientific information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148650906
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148655115

A Brief History of Placebos and Clinical Trials in Psychiatry
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148139761

indialong cites FDA gidance concerning need for placebo in studies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154841
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148154913

TempePhil gives us links to all three Anavex trials:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146017758

TTTav66 analysis of trial recruitment and enrollment figures:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145420519

Worst case enrollment figures:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146083304

2-73 preclinical improvement of learning and behavior:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147390935

A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings (from nidan7500)
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext

Will Canada give Conditional Approval if Australia does?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148221699

How enrollment works:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144955802

Precision Medicine and “The Economics of Drug Development”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144010889

A "sobering read" on precision medicine from Investor2014
https://blogs.sciencemag.org/pipeline/archives/2019/01/31/precision-medicine-real-soon-now

Trial interpretation - What’s in a p value? - a significant read! (from Investor2014)
http://www.evaluate.com/vantage/articles/analysis/vantage-views/whats-p-value

On dosage of 2-73 and P values:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144631198
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495639

Infantile Spasms Market analysis:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147347329

Rett Syndrome Market Analysis:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147347491



In Peace, In War
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist